映恩生物近日宣布,其研发中的DB管线药物已完成临床前研究,并即将进入临床试验阶段。该管线针对特定肿瘤适应症,展现出良好的靶点特异性和潜在治疗优势。目前,映恩生物正按计划推进DB管线的IND申报相关工作,预计在2025年内完成并向监管机构提交申请。此次进展标志着公司在创新生物药研发领域迈出关键一步。映恩生物首席科学官表示,DB管线的成功开发将有助于丰富公司在肿瘤治疗领域的布局,并为未来产品组合提供更...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.